Trial Profile
A Mechanistic Study Of Mifamurtide (MTPPE) In Patients With Metastatic And/Or Recurrent Osteosarcoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Mifamurtide (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms EuroSarc-MEMOS; MEMOS
- 08 Jun 2022 Results reporting design and feasibility outcomes for patients registered into the trial published in the BMC Cancer
- 07 Aug 2019 Status changed from completed to discontinued.
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.